BEONE MEDICINES LTD. Research and Development in Process
BEONE MEDICINES LTD. (ONC) reported Research and Development in Process of $68.67 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-27
- BEONE MEDICINES LTD. research and development in process for the quarter ending 2022-12-31 was $48.66M, a 62.22% increase year-over-year.
- BEONE MEDICINES LTD. research and development in process for the quarter ending 2022-09-30 was $20.00M.
- BEONE MEDICINES LTD. research and development in process for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- BEONE MEDICINES LTD. research and development in process for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- BEONE MEDICINES LTD. research and development in process for fiscal 2022 was $68.67M, a 17.77% decline from fiscal 2021.
- BEONE MEDICINES LTD. research and development in process for fiscal 2021 was $83.50M, a 23.74% decline from fiscal 2020.
- BEONE MEDICINES LTD. research and development in process for fiscal 2020 was $109.50M, a 58.70% increase from fiscal 2019.
- BEONE MEDICINES LTD. research and development in process for fiscal 2019 was $69.00M, a 1.43% decline from fiscal 2018.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $48.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $68.67M derived: sum of 2 quarters · filed 2023-02-27 | $68.67M derived: sum of 3 quarters · filed 2023-02-27 | $68.67M 10-K · filed 2023-02-27 |
| 2022-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $20.00M derived: sum of 2 quarters · filed 2022-11-09 | $20.00M 10-Q · filed 2022-11-09 | $50.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | $30.00M derived: sum of 3 quarters · filed 2023-02-27 | $30.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | $30.00M derived: sum of 2 quarters · filed 2023-02-27 | $30.00M derived: sum of 3 quarters · filed 2023-02-27 | $75.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $30.00M derived: sum of 2 quarters · filed 2023-02-27 | $75.00M derived: sum of 3 quarters · filed 2023-02-27 | $83.50M 10-K · filed 2023-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $45.00M derived: sum of 2 quarters · filed 2022-11-09 | $53.50M 10-Q · filed 2022-11-09 | $73.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $53.50M 10-Q · filed 2022-08-08 | $73.50M derived: sum of 3 quarters · filed 2023-02-27 | $120.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $8.50M 10-Q · filed 2022-05-09 | $28.50M derived: sum of 2 quarters · filed 2023-02-27 | $75.00M derived: sum of 3 quarters · filed 2023-02-27 | $75.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $66.50M derived: sum of 2 quarters · filed 2023-02-27 | $66.50M derived: sum of 3 quarters · filed 2023-02-27 | $109.50M 10-K · filed 2023-02-27 |
| 2020-09-30 | $46.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $46.50M derived: sum of 2 quarters · filed 2021-11-04 | $89.50M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $43.00M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $43.00M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $69.00M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $70.00M 10-K · filed 2021-02-25 |